Tarsus Pharmaceuticals (TARS) Competitors $44.10 +1.45 (+3.40%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$44.09 -0.01 (-0.02%) As of 06/5/2025 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TARS vs. BPMC, BBIO, ELAN, VRNA, TLX, GRFS, TGTX, LEGN, NUVL, and AXSMShould you be buying Tarsus Pharmaceuticals stock or one of its competitors? The main competitors of Tarsus Pharmaceuticals include Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Verona Pharma (VRNA), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Grifols (GRFS), TG Therapeutics (TGTX), Legend Biotech (LEGN), Nuvalent (NUVL), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. Tarsus Pharmaceuticals vs. Blueprint Medicines BridgeBio Pharma Elanco Animal Health Verona Pharma Telix Pharmaceuticals Limited American Depositary Shares Grifols TG Therapeutics Legend Biotech Nuvalent Axsome Therapeutics Blueprint Medicines (NASDAQ:BPMC) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, community ranking, institutional ownership, earnings, analyst recommendations, valuation and dividends. Do institutionals and insiders believe in BPMC or TARS? 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 4.2% of Blueprint Medicines shares are held by insiders. Comparatively, 9.0% of Tarsus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer BPMC or TARS? Blueprint Medicines received 499 more outperform votes than Tarsus Pharmaceuticals when rated by MarketBeat users. However, 67.90% of users gave Tarsus Pharmaceuticals an outperform vote while only 67.15% of users gave Blueprint Medicines an outperform vote. CompanyUnderperformOutperformBlueprint MedicinesOutperform Votes55467.15% Underperform Votes27132.85% Tarsus PharmaceuticalsOutperform Votes5567.90% Underperform Votes2632.10% Do analysts prefer BPMC or TARS? Blueprint Medicines currently has a consensus price target of $129.71, indicating a potential upside of 1.41%. Tarsus Pharmaceuticals has a consensus price target of $66.67, indicating a potential upside of 51.17%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Blueprint Medicines 0 Sell rating(s) 15 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.33Tarsus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media prefer BPMC or TARS? In the previous week, Blueprint Medicines had 63 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 76 mentions for Blueprint Medicines and 13 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.91 beat Blueprint Medicines' score of 0.25 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Blueprint Medicines 18 Very Positive mention(s) 14 Positive mention(s) 26 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Tarsus Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, BPMC or TARS? Blueprint Medicines has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Is BPMC or TARS more profitable? Blueprint Medicines has a net margin of -13.19% compared to Tarsus Pharmaceuticals' net margin of -103.64%. Tarsus Pharmaceuticals' return on equity of -55.86% beat Blueprint Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Blueprint Medicines-13.19% -77.49% -20.84% Tarsus Pharmaceuticals -103.64%-55.86%-39.28% Which has stronger earnings and valuation, BPMC or TARS? Blueprint Medicines has higher revenue and earnings than Tarsus Pharmaceuticals. Blueprint Medicines is trading at a lower price-to-earnings ratio than Tarsus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlueprint Medicines$562.12M14.69-$67.09M-$2.47-51.78Tarsus Pharmaceuticals$233.67M7.93-$135.89M-$2.73-16.15 SummaryBlueprint Medicines and Tarsus Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TARS vs. The Competition Export to ExcelMetricTarsus PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.85B$3.05B$5.46B$8.49BDividend YieldN/A1.60%5.26%4.19%P/E Ratio-11.5732.1527.1119.88Price / Sales7.93450.75410.33155.50Price / CashN/A168.6838.2534.64Price / Book7.413.356.884.60Net Income-$135.89M-$72.17M$3.23B$247.54M7 Day Performance2.70%5.36%2.97%1.82%1 Month Performance-5.06%13.33%9.33%8.90%1 Year Performance36.57%-18.01%27.98%9.82% Tarsus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TARSTarsus Pharmaceuticals2.7677 of 5 stars$44.10+3.4%$66.67+51.2%+31.2%$1.85B$233.67M-11.5750Gap DownBPMCBlueprint Medicines0.9108 of 5 stars$101.50+1.2%$126.56+24.7%+20.9%$6.56B$562.12M-93.98640Trending NewsAnalyst DowngradeBBIOBridgeBio Pharma4.3834 of 5 stars$33.34+1.1%$57.09+71.2%+36.9%$6.33B$127.42M-11.70400ELANElanco Animal Health2.0464 of 5 stars$12.66-0.1%$15.17+19.8%-27.2%$6.29B$4.43B31.669,800Positive NewsVRNAVerona Pharma1.6376 of 5 stars$75.06+3.3%$81.50+8.6%+604.6%$6.09B$118.54M-39.0930Analyst ForecastGap UpTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.60+2.5%$22.00+32.5%N/A$5.61B$783.21M0.00N/ANews CoverageAnalyst ForecastHigh Trading VolumeGRFSGrifols2.7336 of 5 stars$8.11-0.2%N/A+18.8%$5.58B$7.21B6.9326,300TGTXTG Therapeutics2.9642 of 5 stars$34.57+1.0%$40.80+18.0%+137.7%$5.49B$386.39M-345.67290Positive NewsLEGNLegend Biotech3.3026 of 5 stars$28.91-0.5%$76.20+163.6%-27.9%$5.31B$728.30M-30.431,070Gap UpNUVLNuvalent2.2933 of 5 stars$73.49+0.4%$115.50+57.2%+6.1%$5.26BN/A-21.1840Positive NewsAXSMAxsome Therapeutics4.7869 of 5 stars$105.07+0.7%$172.14+63.8%+49.4%$5.17B$432.16M-17.54380Analyst Forecast Related Companies and Tools Related Companies Blueprint Medicines Alternatives BridgeBio Pharma Alternatives Elanco Animal Health Alternatives Verona Pharma Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives Grifols Alternatives TG Therapeutics Alternatives Legend Biotech Alternatives Nuvalent Alternatives Axsome Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TARS) was last updated on 6/6/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredHow to target 627% gains from Trump’s tweetsPresident Trump is shaking up the market with his tweets and Truth Social posts... But while this chaos has...Monument Traders Alliance | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredTrump plotting new lockdown?It's listed inside the White House's own documents: Federal Register notice 90 FR 4544 to be exact. And wh...Porter & Company | SponsoredWhy hasn't Elon tweeted about this?Behind the scenes, there's an entirely different Tesla story brewing… . It's about a quiet stream of income...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.